Wealthfront Advisers LLC Purchases Shares of 5,024 Revvity Inc. $RVTY

Wealthfront Advisers LLC purchased a new position in shares of Revvity Inc. (NYSE:RVTY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,024 shares of the company’s stock, valued at approximately $559,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Revvity in the second quarter worth about $852,070,000. Norges Bank purchased a new position in Revvity during the fourth quarter valued at approximately $80,382,000. Bank of New York Mellon Corp purchased a new position in Revvity during the second quarter valued at approximately $78,766,000. Morgan Stanley lifted its holdings in Revvity by 29.6% in the fourth quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after acquiring an additional 650,083 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in Revvity by 7.0% in the fourth quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock valued at $789,595,000 after acquiring an additional 533,912 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Performance

Shares of RVTY stock opened at $124.88 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $124.97. The business’s 50 day moving average is $111.45 and its two-hundred day moving average is $100.37. The company has a market capitalization of $13.93 billion, a P/E ratio of 59.47, a P/E/G ratio of 2.26 and a beta of 1.07.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business’s revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts expect that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is presently 13.33%.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Stifel Nicolaus cut their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday, May 6th. Evercore reiterated an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. Robert W. Baird set a $117.00 price target on shares of Revvity in a report on Wednesday, May 6th. Finally, Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Revvity has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.